Literature DB >> 17906838

Detection of parvovirus B19 and Chlamydophila pneumoniae in a patient with atypical sarcoidosis.

C Contini1, D Segala, R Cultrera, V M Crapanzano Minichello.   

Abstract

We present an elderly female patient with fever, aplastic anemia, arthralgic symptoms and atypical pneumonia. Serological and clinical findings suggested Parvovirus B19 and Chlamydophila pneumoniae infection. These supposed infections delayed the recognition of underlying sarcoidosis which definitive diagnosis was reached through a lung biopsy and histological demonstration of nonnecrotizing granulomas containing giant cells and noncaseating epithelioid cells. The present case highlights the potential difficulty to diagnose sarcoidosis in the presence of unusual infections which may complicate the course of this disease.

Entities:  

Mesh:

Year:  2007        PMID: 17906838     DOI: 10.1007/s15010-007-6313-7

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   7.455


  15 in total

1.  Löfgren's syndrome as the first manifestation of acute infection due to Chlamydia pneumoniae: a prospective study.

Authors:  I Marie; F Lecomte; H Levesque; C Janvresse; J M Kerleau; N Cailleux; H Courtois
Journal:  Clin Infect Dis       Date:  1999-03       Impact factor: 9.079

2.  Failure to detect the presence of Chlamydia pneumoniae in sarcoid pathology specimens.

Authors:  F Blasi; G Rizzato; M Gambacorta; R Cosentini; R Raccanelli; P Tarsia; C Arosio; E Savini; C Cantoni; L Fagetti; L Allegra
Journal:  Eur Respir J       Date:  1997-11       Impact factor: 16.671

3.  Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals.

Authors:  Corinna Hermann; Kathrin Graf; Annemarie Groh; Eberhard Straube; Thomas Hartung
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

4.  Comparison of individuals with and without specific IgA antibodies to Chlamydia pneumoniae: respiratory morbidity and the metabolic syndrome.

Authors:  Göran Falck; Judy Gnarpe; Lars-Olof Hansson; Kurt Svärdsudd; Håkan Gnarpe
Journal:  Chest       Date:  2002-11       Impact factor: 9.410

5.  Serological response to Chlamydia pneumoniae in patients with sarcoidosis.

Authors:  M Puolakkainen; L A Campbell; C C Kuo; M Leinonen; C Grönhagen-Riska; P Saikku
Journal:  J Infect       Date:  1996-11       Impact factor: 6.072

6.  A seroepidemiologic study of Chlamydia pneumoniae in Rhode Island. Evidence of serologic cross-reactivity.

Authors:  D G Kern; M A Neill; J Schachter
Journal:  Chest       Date:  1993-07       Impact factor: 9.410

Review 7.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

8.  Chlamydia pneumoniae DNA is not detectable within sarcoidosis tissue.

Authors:  G D Mills; R K Allen; P Timms
Journal:  Pathology       Date:  1998-08       Impact factor: 5.306

9.  Hilar lymphadenopathy associated with Chlamydia pneumoniae infection.

Authors:  O Haugen; S Ritland
Journal:  Scand J Infect Dis       Date:  1992

10.  Severe prolonged red blood cell aplasia and thrombocytopenia induced by parvovirus B19 infection in a patient with sarcoidosis.

Authors:  Jean-François Viallard; Marie Parrens; Olivier Hermine; Jean-Michel Boiron; Marie-Edith Lafon; Gérald Marit; Josy Reiffers; Jean-Luc Pellegrin
Journal:  Clin Infect Dis       Date:  2003-01-06       Impact factor: 9.079

View more
  2 in total

1.  Detection of Chlamydophila pneumoniae in patients with arthritis: significance and diagnostic value.

Authors:  Carlo Contini; Anastasio Grilli; Lorenzo Badia; Viola Guardigni; Marcello Govoni; Silva Seraceni
Journal:  Rheumatol Int       Date:  2010-04-10       Impact factor: 2.631

2.  Detection of parvovirus B19 in the lower respiratory tract.

Authors:  Cristina Costa; Maria Elena Terlizzi; Paolo Solidoro; Daniela Libertucci; Massimiliano Bergallo; Rossana Cavallo
Journal:  J Clin Virol       Date:  2009-07-24       Impact factor: 3.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.